Reply to: Adjuvant Treatment Options and Modalities in Pancreatic Adenocarcinoma: Insights From ESPAC4

Affiliations

¹ Daniel H. Palmer, PhD and Richard J. Jackson, PhD, University of Liverpool, Liverpool, United Kingdom; Christoph Springfeld, MD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Thilo Hackert, MD, Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Christoph W. Michalski, MD and John P. Neoptolemos, MD, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.

Daniel H Palmer et al. J Clin Oncol. 2025 Jul.

. 2025 Jul;43(19):2229-2230.

doi: 10.1200/JCO-25-00333. Epub 2025 Mar 31.

¹ Daniel H. Palmer, PhD and Richard J. Jackson, PhD, University of Liverpool, Liverpool, United Kingdom; Christoph Springfeld, MD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Thilo Hackert, MD, Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and Christoph W. Michalski, MD and John P. Neoptolemos, MD, Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.

No abstract available

LinkOut - more resources